Olatec Industries

Olatec Therapeutics is a clinical-stage biotechnology company focused on developing a new class of oral, small molecule inhibitors of the NLRP3 inflammasome. The company's lead candidate, OLT1177 (dapansutrile), is being evaluated in multiple clinical trials for inflammatory conditions including gouty arthritis, heart failure, and acute myocardial infarction. Olatec leverages its proprietary platform to target the IL-1 pathway, aiming to provide safer and more effective treatments for chronic and acute inflammatory diseases. The company maintains significant academic collaborations to advance its pipeline across diverse therapeutic areas such as neurology and oncology. Olatec is headquartered in New York and operates as a private entity.